safety and immunogenicity of boosting bcg vaccinated subjects with bcg comparison with boosting with a new tb vaccine, mva85a提高bcg接种疫苗的安全性和免疫原性主题与bcg比较增加一个新的结核病疫苗,mva85a.pdfVIP

safety and immunogenicity of boosting bcg vaccinated subjects with bcg comparison with boosting with a new tb vaccine, mva85a提高bcg接种疫苗的安全性和免疫原性主题与bcg比较增加一个新的结核病疫苗,mva85a.pdf

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
safety and immunogenicity of boosting bcg vaccinated subjects with bcg comparison with boosting with a new tb vaccine, mva85a提高bcg接种疫苗的安全性和免疫原性主题与bcg比较增加一个新的结核病疫苗,mva85a

Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A 1. 1. 1 1 2 Kathryn T. Whelan , Ansar A. Pathan , Clare R. Sander , Helen A. Fletcher , Ian Poulton , Nicola C. 3 1 1 Alder , Adrian V. S. Hill , Helen McShane * 1Jenner Institute, University of Oxford, Churchill Hospital, Oxford, United Kingdom, 2 Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, United Kingdom, 3 Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom Abstract Objectives: To investigate the safety and immunogenicity of a booster BCG vaccination delivered intradermally in healthy, BCG vaccinated subjects and to compare with a previous clinical trial where BCG vaccinated subjects were boosted with a new TB vaccine, MVA85A. Design: Phase I open label observational trial, in the UK. Healthy, HIV-negative, BCG vaccinated adults were recruited and vaccinated with BCG. The primary outcome was safety; the secondary outcome was cellular immune responses to antigen 85, overlapping peptides of antigen 85A and tuberculin purified protein derivative (PPD) detected by ex vivo interferon- gamma (IFN-c) ELISpot assay and flow cytometry. Results and Conclusions: BCG revaccination (BCG-BCG) was well tolerated, and boosting of pre-existing PPD-specific T cell responses was observed. However, when these results were compared with data from a previous clinical trial, where BCG was boosted with MVA85A (BCG-MVA85A), MVA85A induced significantly higher levels (.2-fold) of antigen 85-specific CD4+ T cells (both antigen and peptide pool responses) than boost

您可能关注的文档

文档评论(0)

xyz118 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档